Abstract: The present invention provides methods of ameliorating or reducing the extent of cardiac arrhythmia disorders, by administering an inhibitor of histone deacetylase enzyme (HDAC).

Abstract: The present invention provides methods for dilating the bronchi or bronchioles and relaxing a pulmonary smooth muscle in a subject by treating the subject with a pharmaceutical composition, which includes a Histone deacetylase (HDAC) inhibitor. The ability to dilate the bronchi or bronchioles and relax a pulmonary smooth muscle according to the methods of the invention allows treating, alleviating, or inhibiting bronchoconstrictive diseases or disorders and symptoms associated or derived from bronchoconstrictive diseases.

Abstract: The present invention provides methods of ameliorating or reducing the extent of cardiac arrhythmia disorders, by administering an inhibitor of histone deacetylase enzyme (HDAC).

Abstract: The present invention provides methods for dilating the bronchi or bronchioles and relaxing a pulmonary smooth muscle in a subject by treating the subject with a pharmaceutical composition, which includes a Histone deacetylase (HDAC) inhibitor. The ability to dilate the bronchi or bronchioles and relax a pulmonary smooth muscle according to the methods of the invention allows treating, alleviating, or inhibiting bronchoconstrictive diseases or disorders and symptoms associated or derived from bronchoconstrictive diseases.

Abstract: The present invention provides methods of ameliorating or reducing the extent of ischemic injury, reperfusion injury, and myocardial infarction, by administering an inhibitor of histone deacetylase enzyme (HDAC) or an inhibitor of DNA methyltransferase enzyme (DNMT).

Abstract: The present invention provides methods of ameliorating or reducing the extent of ischemic injury, reperfusion injury, and myocardial infarction, by administering an inhibitor of histone deacetylase enzyme (HDAC) or an inhibitor of DNA methyltransferase enzyme (DNMT).

Abstract: The present invention provides methods of ameliorating or reducing the extent of ischemic injury, reperfusion injury, and myocardial infarction, by administering an inhibitor of histone deacetylase enzyme (HDAC) or an inhibitor of DNA methyltransferase enzyme (DNMT).

Abstract: The present invention provides methods of ameliorating or reducing the extent of ischemic injury, reperfusion injury, and myocardial infarction, by administering an inhibitor of histone deacetylase enzyme (HDAC) or an inhibitor of DNA methyltransferase enzyme (DNMT).

Abstract: The present invention provides methods for dilating the bronchi or bronchioles and relaxing a pulmonary smooth muscle in a subject by treating the subject with a pharmaceutical composition, which includes a Histone deacetylase (HDAC) inhibitor. The ability to dilate the bronchi or bronchioles and relax a pulmonary smooth muscle according to the methods of the invention allows treating, alleviating, or inhibiting bronchoconstrictive diseases or disorders and symptoms associated or derived from bronchoconstrictive diseases.

Abstract: The present invention provides methods and kits for predicting transplant rejection or tolerance. Methods for predicting the probability of cardiac allograft rejection via profiling of peripheral blood gene expression are also provided.

Abstract: The present disclosure relates to the measurement of the audience characteristics or demographics which is or can be exposed to displayed interactive content depicted on a screen. The audience can include persons who are engaged in interacting with the interactive content as well as persons who are observers of the interactive content and/or the active participants. The content can include one or more targeted advertisements contained in or associated with interactive content, and can be varied based on the audience characteristics or demographics. The audience characteristics or demographics can be used to accurately charge advertisers for the impressions created by the content displayed and can also or alternatively be used to determine and/or trigger what content is actually displayed.

Abstract: The present disclosure relates to the measurement of the audience characteristics or demographics which is or can be exposed to displayed interactive content depicted on a screen. The audience can include persons who are engaged in interacting with the interactive content as well as persons who are observers of the interactive content and/or the active participants. The content can include one or more targeted advertisements contained in or associated with interactive content, and can be varied based on the audience characteristics or demographics. The audience characteristics or demographics can be used to accurately charge advertisers for the impressions created by the content displayed and can also or alternatively be used to determine and/or trigger what content is actually displayed.

Abstract: The present invention provides methods of ameliorating or reducing the extent of cardiac arrhythmia disorders, by administering an inhibitor of histone deacetylase enzyme (HDAC).

Abstract: The present invention provides methods of ameliorating or reducing the extent of ischemic injury, reperfusion injury, and myocardial infarction, by administering an inhibitor of histone deacetylase enzyme (HDAC) or an inhibitor of DNA methyltransferase enzyme (DNMT).

Abstract: The present disclosure relates to the measurement of the audience characteristics or demographics which is or can be exposed to displayed interactive content depicted on a screen. The audience can include persons who are engaged in interacting with the interactive content as well as persons who are observers of the interactive content and/or the active participants. The content can include one or more targeted advertisements contained in or associated with interactive content, and can be varied based on the audience characteristics or demographics. The audience characteristics or demographics can be used to accurately charge advertisers for the impressions created by the content displayed and can also or alternatively be used to determine and/or trigger what content is actually displayed.

Abstract: The present invention provides methods and kits for predicting transplant rejection or tolerance. Methods for predicting the probability of cardiac allograft rejection via profiling of peripheral blood gene expression are also provided.